Abstract: The present invention relates to a novel protein skeletal module which increases the binding affinity or binding specificity of active polypeptides. More particularly, the present invention relates to a protein skeletal module comprising polypeptides consisting of the 1st to 19th amino acids of the amino acid sequence expressed in sequence number 1; polypeptides comprising active polypeptides; and polypeptides consisting of the 29th to 86th amino acids of the amino acid sequence expressed in sequence number 1. The present invention also relates to a method for preparing the protein skeletal module. The protein skeletal module of the present invention increases the binding affinity or binding specificity of active polypeptides embedded therein, and therefore is effective in diagnosing and treating diseases.
Type:
Application
Filed:
October 18, 2013
Publication date:
March 20, 2014
Applicant:
KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventors:
Kiweon CHA, In-Seop So, Soyoun Kim, Byung-Heon Lee, In San Kim
Abstract: The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences.
Type:
Application
Filed:
September 17, 2013
Publication date:
March 13, 2014
Applicant:
CSL BEHRING GMBH
Inventors:
Thomas Weimer, Stefan Schulte, Hubert Metzner, Ulrich Kronthaler, Holger Lind, Wiegand Lang
Abstract: The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
Type:
Application
Filed:
October 1, 2013
Publication date:
March 13, 2014
Applicants:
MUSC Foundation for Research Development, The Regents of the University of Colorado, a Body Corporate
Inventors:
Gary GILKESON, Stephen Tomlinson, V. Michael Holers, Baerbel Rohrer
Abstract: Non-human totipotent or pluripotent cells are provided comprising at a genomic locus a self-excisable, recombinase expression cassette flanked with recombination recognition sites, wherein a recombinase gene is operably linked to a promoter that is active in a post-meiotic spermatid stage when cytoplasmic bridging occurs between spermatids. Compositions and methods are provided for making cassette-deleted F1 non-human animals, wherein the methods comprise employing totipotent or pluripotent cells containing a self-excisable, recombinase expression cassette.
Type:
Application
Filed:
November 13, 2013
Publication date:
March 13, 2014
Applicant:
Regeneron Pharmaceuticals, Inc.
Inventors:
Guochun Gong, Ka-Man Venus Lai, David Frendewey, David M. Valenzuela
Abstract: This disclosure relates to vectors, isolated cells, compositions, and methods for the treatment of critical limb ischemia and associated disorders. One aspect of the disclosure relates to a vector comprising a nucleic acid encoding a 165A isoform VEGF protein and a promoter that regulates expression of the nucleic acid encoding the VEGF.
Type:
Application
Filed:
March 15, 2013
Publication date:
March 6, 2014
Applicant:
The Regents of the University of California
Inventors:
Jan Nolta, Karen Pepper, Fernando Fierro, Gerhard Bauer
Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
Type:
Application
Filed:
March 15, 2013
Publication date:
March 6, 2014
Applicants:
UNIVERSITY OF VIENNA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Jennifer A. Doudna, Martin Jinek, Emmanuelle Charpentier, Krzysztof Chylinski, James Harrison Doudna Cate, Wendell Lim, Lei Qi
Abstract: The invention relates to a modified lymphoid cell having gene conversion fully or partially replaced by hypermutation, wherein said cell has no deleterious mutations in genes encoding paralogues and analogues of the RAD51 protein, and wherein said cell is capable of directed and selective genetic diversification of a target nucleic acid by hypermutation or a combination of hypermutation and gene conversion. The invention also relates to a method for diversifying any transgenic target gene in said cell. Preferably, the target gene is integrated into the immunoglobulin light or heavy chain locus by targeted integration.
Abstract: The present invention relates to methods of host cell transduction utilizing ecotropic retroviral vector particles. The retroviral vector particle may comprise an envelope of Friend murine leukaemia virus, in particular the envelope encoded by molecular clone PVC-211 and the host cell may be engineered to recombinantly express the Reel receptor. The retroviral vector particles and methods of the invention can be used to introduce expressible polynucleotide sequences of interest into host cells with high efficiency. This results in protein production methods with higher yield (mg/L) and a reduction in manufacturing costs that could be used in a range of applications including for example, the production of therapeutic proteins, vaccines and antibodies.
Abstract: The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes.
Type:
Application
Filed:
November 1, 2013
Publication date:
February 27, 2014
Applicant:
NOVARTIS AG
Inventors:
Mark Aron LABOW, Larry Alexander GAITHER, Jason BORAWSKI
Abstract: The present invention is directed generally to cell culture media useful for introducing macromolecules and compounds (e.g., nucleic acid molecules) into cells (e.g., eukaryotic cells in the presence of said media. Cells containing introduced materials can be further cultured in the media. In particular, the invention allows introduction of nucleic acid molecules (e.g., vectors) into cells (particularly eukaryotic cells) and expression of proteins encoded by the nucleic acid molecules in the cells. The invention obviates the need to change the cell culture medium each time a different procedure is performed with the cells (e.g., culturing cells vs. transfecting cells). The invention thus provides efficient and high throughput methods to transform/transfect culture and cells avoiding the need for multiple manipulations and transfers of cells during transfection and expression studies.
Type:
Application
Filed:
August 15, 2013
Publication date:
February 27, 2014
Applicant:
LIFE TECHNOLOGIES CORPORATION
Inventors:
Valentina C. CICCARONE, Dale Gruber, Shelly Bennett
Abstract: Increased in vivo and/or in vitro stability is imparted to a biologically active protein by fusing to an amino acid sequence consisting of at least about 100 amino acid residues, which consist essentially of Alanine, Serine and Proline, which form a random coil conformation. Specific examples are described. Also described are related nucleic acids, vectors and cells encoding such amino acids; compositions of biologically active proteins fused to a random coil domain, and methods of making and using the compounds and compositions of the invention.
Type:
Application
Filed:
August 9, 2013
Publication date:
February 20, 2014
Applicant:
TECHNISCHE UNIVERSITAT MUNCHEN
Inventors:
Ame Skerra, Ina Theobald, Martin Schlapschy
Abstract: A method for regenerating pancreatic tissue using recombinant periostin protein, a nucleic acid encoding said periostin and pharmaceutical compositions comprising said periostin are disclosed. Isolation of a nucleic acid encoding a periostin isoform, panc, is also taught.
Abstract: The present disclosure relates to methods of decreasing lactate production in cell culture using divalent transitional metallic salts. The present disclosure also relates to a method of producing polypeptide by adding divalent transitional metallic salt to the cell culture medium for reducing lactate accumulation followed by fermenting and recovering the polypeptide.
Abstract: The present invention concerns constructs based on sequences derived from the partitioning system of plasmid and chromosomal DNA of bacteria, such as eukaryotic expression vectors, fusion proteins and polynucleotides encoding the same and also eukaryotic cells transformed with or expressing such constructs. The present invention also concerns the use thereof in the regulation of gene expression and/or in the detection and control of the dynamics, localization or metabolism of genomic DNA loci of interest in eukaryotic cells.
Type:
Application
Filed:
March 23, 2012
Publication date:
February 13, 2014
Applicant:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
Kerstin Bystricky, Franck Gallardo, David Lane, Nelly Dubarry
Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
Abstract: A biological photoreceptor, which is a directly light-controlled ion channel, including (i) an apoprotein and (ii) a light-sensitive polyene covalently bound to the apoprotein, the polyene interacting with the apoprotein and functioning as a direct light-sensitive gate.
Type:
Grant
Filed:
April 23, 2012
Date of Patent:
February 11, 2014
Assignee:
Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.
Inventors:
Peter Hegemann, Georg Nagel, Ernst Bamberg
Abstract: The invention relates to polypeptides and polynucleotides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover, and uses of same in the prevention, diagnosis and treatment of conditions requiring regulation of trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover. In particular aspects, diagnostic methods are disclosed for evaluating conditions such as preeclampsia utilizing matador polypeptides and polynucleotides encoding same.
Type:
Application
Filed:
February 28, 2013
Publication date:
February 6, 2014
Applicant:
MT. SINAI HOSPITAL
Inventors:
Isabella Caniggia, Martin Post, Nima Soleymanlou, Andrea Jurisicova
Abstract: There is provided an expression vector for animal cell having an increased gene expression efficiency, and particularly, an expression vector for animal cells including a MAR element and a SAR element, which are gene expression increasing factors, at a 5? end of a promoter, a 3? end of a transcription termination site, or at both of the 5? end of the promoter and the 3? end of the transcription termination site. The expression vector for animal cells according to the present invention exhibits remarkably increased gene expression efficiency as compared to conventional expression vectors for animal cells, such that protein expression of foreign genes may be significantly increased using this expression vector for animal cells. Particularly, the expression vector for animal cells according to the present invention may be useful in that a high-expression cell line may be secured even without MTX amplification.
Type:
Application
Filed:
March 30, 2012
Publication date:
February 6, 2014
Applicant:
PANGEN BIOTECH INC.
Inventors:
Jaeseung Yoon, Kwanghee Baek, Taeho Byun, JeongSoo Park
Abstract: A short human genomic nucleotide sequence from the SAR3 region of the human interferon ?2 gene permits enhances expression stability in the absence of drug selection and permits generation of stable clones or stable pools of cells for producing recombinant proteins. Although stable clones may be generated, the ability to generate stable pools reduces the burden of generating stable clones.
Abstract: Provided is a polynucleotide encoding a protein having an activity to transfer a sugar to the hydroxy groups at the 4?- and 7-positions of a flavone.
Abstract: Methods for producing compositions of decellularized extracellular matrix (DM) tissue culture are described. The compositions can be used for coating supports such as tissue culture substrates, osteogenic gels, and medical devices.
Type:
Application
Filed:
April 16, 2012
Publication date:
January 23, 2014
Applicant:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
J. Kent Leach, Martin Decaris, Archana Bhat
Abstract: A system and method of adapting host cells to suspension cell culture and suspension cell lines ATCC PTA-12593 and ATCC PTA-12461 produced thereby are disclosed. The method includes the serial replating of substantially undiluted culture cells onto a surface area until cell clumps are visualized and then, upon cell clumping, moving the cells into a suspension culture system.
Type:
Application
Filed:
July 1, 2013
Publication date:
January 9, 2014
Inventors:
Gabriela D.C. Denning, Richard E. Gautney
Abstract: The invention relates to methods of selecting a cardiomyocyte from a cell population derived from a whole heart or a differentiated cell population derived from a stem cell without genetic alteration. Specifically, the invention relates to a method of selecting a cardiomyocyte from a cardiomyocyte-containing cell mixture without genetic alteration of a cardiomyocyte, on the basis of a relative content of cellular mitochondria and/or a relative mitochondrial transmembrane potential of the cell. The invention also relates to methods of enriching a cardiomyocyte from a cardiomyocyte-containing cell mixture without genetic alteration of a cardiomyocyte, producing a cardiomyocyte without genetic alteration of a cardiomyocyte, and evaluating the ratio of a cardiomyocyte in a cardiomyocyte-containing cell mixture.
Type:
Grant
Filed:
August 26, 2005
Date of Patent:
January 7, 2014
Assignees:
Daiichi Sankyo Company, Limited, Keio University
Abstract: Disclosed are isolated mutant erythropoietin (EPO) polypeptides, functional fragment thereof, nucleic acid encoding such peptides, vectors including such nucleic acids and compositions including such peptides and nucleic acids. The mutant EPO peptides are unique in that they include a substitution at amino acid position number 76, such as a glutamic acid for arginine substitution at position 76. This substitution inhibits erythropoietic activity while retaining their neuroprotection. Also disclosed are methods of treating or inhibiting neuronal degeneration, reducing or inhibiting one or more symptoms associated with neuronal degeneration and/or glaucoma in a subject. The methods include administering a therapeutically effective amount of a isolated mutant erythropoietin EPO polypeptide, an expression vector encoding such a mutant erythropoietin EPO polypeptide, a viral particle including an expression vector, or a composition, thereby treating or inhibiting neuronal degeneration in the subject.
Type:
Application
Filed:
January 13, 2012
Publication date:
January 2, 2014
Applicant:
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
Abstract: The present invention is related to a cell culture medium for the expression of a protein, which medium comprises a PAM inhibitor, or a physiological equivalent thereof, and to a cell culture process for the expression of a protein, in which process a PAM inhibitor, or a physiological equivalent thereof, is used (FIG. 1).
Type:
Application
Filed:
November 9, 2011
Publication date:
December 19, 2013
Applicant:
SANDOZ GMBH
Inventors:
Corinna Sonderegger, Julia Schmutzhard, Christine Heel, Thomas Stangler
Abstract: Two vIRF4 (Kaposi's-sarcoma-associated-herpesvirus vIRF4) peptides, vif1, corresponding to aa202-216 of vIRF4, and vif2, corresponding to aa220-236 of vIRF4, are potent and selective HAUSP antagonists. The vif1 and vif2 peptides robustly suppress HAUSP DUB enzymatic activity, ultimately leading to p53-mediated anti-cancer activity. The vif1 and vif2 peptides, along with their homologues, are useful in treating cancer through regulation of p53 activity in a cancer cell. Also disclosed is the crystalline structure of vIRF4-HAUSP TRAF domain complex. The structure is useful in computer aided drug design for identifying an agent that interacts with and inhibits HAUSP, resulting in p53 medicated cell cycle arrest of cancer cells.
Abstract: Methods are disclosed for producing proteins having biological activity for blood coagulation mediated by Factor VIIa or Factor IX. The proteins are produced by mammalian host cells which have been stably transfected with a DNA construct containing a nucleotide sequence which codes at least partially for either Factor VII or Factor IX. The nucleotide sequence comprises a first nucleotide sequence encoding a calcium binding domain, joined to a second nucleotide sequence positioned downstream of the first sequence. The second sequence encodes a catalytic domain for the serine protease activity of either Factor VIIa or Factor IX. The joined sequences code for proteins having substantially the same biological activity for blood coagulation as either Factor VIIa or Factor IX.
Type:
Grant
Filed:
September 25, 1991
Date of Patent:
December 10, 2013
Assignee:
ZymoGenetrics, Inc.
Inventors:
Frederick S. Hagen, Mark J. Murray, Sharon J. Busby, Kathleen L. Berkner, Margaret Y. Insley, Richard G. Woodbury, Charles L. Gray
Abstract: The present invention belongs to the field of animal health and relates to a nucleic acid sequence which comprises the complete genome of an infectious Schmallenberg virus (SBV) useful for studying viremia and diseases caused by SBV in ruminants, and in the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of viremia and diseases caused by SBV.
Type:
Application
Filed:
May 29, 2013
Publication date:
December 5, 2013
Applicant:
BOEHRINGER INGELHEIM VETMEDICA GMBH
Inventors:
Ilona REIMANN, Martin BEER, Kerstin WERNIKE
Abstract: The present invention describes material and methods related to synthetic peptides which block the secretion of neurotransmitters and induce muscle relaxation, and use of said peptides as inhibitors of neurotransmitter secretion and muscle contraction, and as inducers of muscle relaxation.
Type:
Application
Filed:
November 26, 2012
Publication date:
December 5, 2013
Applicant:
PARTNERSHIP & CORP. TECHNOLOGY TRANSFER
Abstract: C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.
Type:
Application
Filed:
July 10, 2013
Publication date:
November 28, 2013
Applicant:
University of Pittsburgh - Of the Commonwealth System of Higher Education
Inventors:
Carol A. Feghali-Bostwick, Yukie Yamaguchi
Abstract: Non-natural albumin binding domains, polynucleotides encoding thereof and methods of making and using these domains and polynucleotides are useful in controlling the half-life of therapeutic molecules for patients.
Abstract: The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding a) a secretion peptidic signal, b) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC 2.1.1.63), a mutant or a catalytic domain thereof, and c) a recombinant protein. Said MGMT enzyme is preferably the so-called SNAP protein.
Type:
Application
Filed:
December 9, 2011
Publication date:
November 21, 2013
Inventors:
Philippe Despres, Sylvie Paulous, Elodie Crublet
Abstract: Provided herein is a synthetic or isolated polynucleotide encoding a mammalian 18S rRNA that is resistant to pactamycin. The pactamycin-resistance is conferred by one or more single residue substitutions in the 18S rRNA sequence; a fragment thereof harboring said substitutions; a complementary sequence thereto; or a substantially identical sequence of the foregoing. Related systems, methods and kits are also described.
Type:
Application
Filed:
May 21, 2013
Publication date:
November 21, 2013
Inventors:
Vincent P. Mauro, Luke Burman, Gerald M. Edelman
Abstract: This invention relates to a cell comprising a reporter gene under control of an ARIA gene promoter, the cell being used for searching for an agent for prevention or treatment of diseases attributed to reduced insulin sensitivity, for searching for an obesity-controlling substance, or for searching for an obesity-inducing substance.
Type:
Application
Filed:
January 20, 2012
Publication date:
November 14, 2013
Applicant:
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
Inventors:
Koji Ikeda, Hiroaki Matsubara, Yoshiki Akakabe
Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
Type:
Application
Filed:
May 9, 2013
Publication date:
November 14, 2013
Applicant:
CODEXIS,INC.
Inventors:
CHEN Haibin, Steven J. Collier, Jovana NAZOR, Joly SUKUMARAN, Derek SMITH, Jeffrey C. MOORE, Gregory HUGHES, Jacob JANEY, Gjalt HUISMAN, Scott NOVICK, Nicholas AGARD, Oscar ALVIZO, Gregory COPE, Wan Lin YEO, Stephanie NG
Abstract: Tissues produced by culture of cells produced by nuclear transfer on a matrix derived from nuclear transfer embryos or embryos and pluripotent cells provided by other methods are provided. These tissues are useful for cell therapy.
Abstract: The present invention provides a nucleic acid construct for expressing an oxidative stress indicator comprising: a nucleic acid sequence encoding an Nrf2 protein-derived partial protein that comprises at least an Neh2 domain sequence and substantially lacks or is functionally deficient in an Neh1 domain sequence or an Neh1-Neh3 domain sequence; a stress-inducible promoter sequence positioned upstream of the nucleic acid sequence encoding an Nrf2 protein-derived partial protein; and a nucleic acid sequence encoding a protein capable of generating a detectable signal, the nucleic acid sequence being positioned downstream of the nucleic acid sequence encoding an Nrf2 protein-derived partial protein. The present invention also provides a method for measuring oxidative stress and a method for screening for an anti-oxidative stress agent, using the nucleic acid construct.
Abstract: Disclosed is a fusion protein comprising blood coagulation factor IX (FIX) and transferrin. The fusion protein exhibits improved specific FIX activity, as compared to native FIX, and can be useful in the treatment of FIX deficiency-associated diseases.
Type:
Application
Filed:
October 19, 2011
Publication date:
November 7, 2013
Applicant:
SK CHEMICALS CO., LTD.
Inventors:
Min Sun Lee, Hun-Taek Kim, Bong-yong Lee, Mahn Hoon Park, Yun Jung Lim
Abstract: The present invention relates to a gene encoding Synechocystis putative DNA binding stress protein (SyDBSP protein) derived from cyanobacteria Synechocystis PCC6906; a method for enhancing the salt tolerance of a plant comprising transforming a plant cell with a recombinant vector comprising the SyDBSP gene and overexpressing the SyDBSP gene; a plant having enhanced salt tolerance produced by the aforementioned method, and seed of the plant.
Type:
Application
Filed:
October 13, 2011
Publication date:
October 31, 2013
Applicant:
KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
Inventors:
Jang Ryol Liu, Suk Weon Kim, Jong Hyun Kim, Sung Ran Min, Won Joong Jeong, Myung Suk Ahn, Young Min Park, Myung Jin Oh, Ji Hyun Park
Abstract: Disclosed herein are flowable tissue matrix compositions comprising small pieces of partially or completely decellularized tissue suspended in a gelatinized tissue or gelatin gel comprising partially or completely decellularized tissue or synthetic gelatin. The flowable tissue matrix compositions can contain factors that promote or enhance native cell migration, proliferation, and/or revascularization after implantation into a subject. Also disclosed are methods of making and using the flowable tissue matrix compositions. The compositions can be implanted into a tissue in need of repair, regeneration, healing, treatment, and/or alteration, and can promote or enhance native cell migration, proliferation, and/or revascularization.
Abstract: The present invention is further directed to methods and compositions for modulating the activity of the Toso protein. The invention further encompasses treatment of disorders associated with inflammation, autoimmune disorders, and cancer using compositions that include a soluble Toso protein.
Type:
Application
Filed:
March 14, 2013
Publication date:
October 24, 2013
Inventors:
Michael W. Tusche, Tak W. Mak, Pamela S. Ohashi, Philipp Lang, Karl Lang, Dirk Brenner, Gloria Lin
Abstract: The present invention provides methods of reducing nonprocessed Factor VIII or a chimeric polypeptide comprising Factor VIII comprising co-transfecting in a host cell a polynucleotide encoding Factor VIII with a polynucleotide encoding a protein convertase, where the endogenous processing enzymes of the host cell are insufficient to convert all of the Factor VIII to its processed isoform; expressing a proprotein convertase from a second polynucleotide in the host cell; and reducing the nonprocessed Factor VIII by processing with said proprotein convertase.
Abstract: The invention relates to mutant channelrhodopsins having improved properties, nucleic acid constructs encoding same, expression vectors carrying the nucleic acid construct, cells comprising said nucleic acid construct or expression vector, and their respective uses.
Type:
Application
Filed:
September 8, 2011
Publication date:
October 24, 2013
Applicant:
Max-Planck-Gesellschaft zur Foerderung der Wissenschaftern e.V.
Inventors:
Ernst Bamberg, Christian Bamann, Sonja Kleinlogel, Phillip Wood, Robert E. Dempski
Abstract: The present invention provides culture media and methods of culturing pluripotent stem cells, such as epiblast stem cells (EpiSCs) and embryonic stem cells (ESCs), in order to culture, derive, and reprogram pluripotent stem cells, such as converting ESCs to EpiSCs.
Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.
Type:
Application
Filed:
November 2, 2012
Publication date:
October 17, 2013
Inventors:
Austin GURNEY, John Lewicki, Sanjeev Satyal, Timothy Hoey
Abstract: The present invention relates to methods, systems, and kits for intoxicating cells, neuronal and non-neuronal cells, with a toxin or fragment thereof. This is done by subjecting toxin substrate and a lipid or polymeric carrier (e.g., DNA uptake facilitating agent) to one or more cells for use in cell based assays. In an aspect, the methods of the present invention allow for high throughput assays and, as such, for the evaluation of drug candidates.
Type:
Application
Filed:
June 25, 2013
Publication date:
October 17, 2013
Inventors:
George A. Oyler, Charles B. Shoemaker, Chuehling Kuo